Abstract
Sjögren-Larsson Syndrome (SLS) is caused by an autosomal recessive defect in the gene coding for fatty aldehyde dehydrogenase (FALDH), an enzyme necessary for the oxidation of long-chain aliphatic aldehydes to fatty acid as one enzyme of the fatty alcohol:nicotinamide-adenine dinucleotide (NAD+)-oxidoreductase complex (FAO). The impaired activity of FALDH leads to the clinical symptom triad of generalized ichthyosis, mental retardation, and spastic diplegia or tetraplegia. Treatment options are primarily symptomatic. Gene therapy by means of genetic reintroduction of the functional FALDH gene into defective cells has so far not been considered as a therapeutic modality. In order to pursue such an approach for SLS, we constructed a recombinant adeno-associated virus-2 vector containing the human cDNA of functional FALDH and evaluated its capability to restore the enzyme-deficiency in a FALDH-deficient cell line resembling the gene defect of SLS. rAAV-2 transduction of FALDH-deficient cells, usually exhibiting less than 10% of normal FALDH activity, resulted in an increase of FALDH activity within the range of unaffected cells. Moreover, FALDH-transduced cells regained resistance over exposure to long chain aldehydes, which are otherwise toxic to FALDH-deficient cells. These results indicated that rAAV-2 vectors are able to restore FALDH-deficiency in a cell system resembling SLS. The findings give the first support to the concept that gene therapy might be a future option for the treatment of SLS.
This is a preview of subscription content, log in via an institution to check access.
Abbreviations
- rAAV-2:
-
Recombinant adeno-associated virus type 2
- CHO:
-
Chinese hamster ovary cells
- FALDH:
-
Fatty aldehyde dehydrogenase
- GFP:
-
Green fluorescent protein
- SLS:
-
Sjögren-Larsson syndrome
References
Braun-Falco M, Doenecke A, Smola H, Hallek M (1999) Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Therapy 6:432–441
Braun-Falco M, Eisenried A, Büning H, Ring J (2005) Recombinant adeno-associated virus type 2-mediated gene transfer into human keratinocytes is influenced by both ubiquitin/proteasome pathway and epidermal growth factor-receptor tyrosine kinase. Arch Dermatol Res 296:528–535
Büning H, Braun-Falco M, Hallek M (2004) Progress in the use of adeno-associated virus vectors for gene therapy. Cells Tis Org 177:139–150
De Laurenzi V, Rogers GR, Hamrock DJ, Marekov LN, Steinert PM, Compton JG, Markova N, Rizzo WB (1996) Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nature Genetics 12:52–57
James PF, Zoeller RA (1997) Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase. J Biol Chem 272:23532–23539
Kelson TL, Craft DA, Rizzo WB (1992) Carrier detection for Sjögren-Larsson syndrome. J Inherited Metab Dis 15:105–111
Kelson TL, Secor McVoy JR, Rizzo WB (1997) Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization. Biochimica et Biophysica Acta 1335:99–110
Möhrenschlager M, Rizzo WB, Kraus CS, Limbrock J, Cohen M, Anton-Lamprecht I, Abeck D, Ring J (2000) Sjögren-Larsson-Syndrom. Hautarzt 51:250–255
Rizzo WB, Craft DA (1991) Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblast. J Clin Invest 88:1643–1648
Rizzo WB (1993) Sjögren-Larsson Syndrome. Sem Dermatol 12:210–218
Rizzo WB, Carney G, Lin Z (1999) The molecular basis of Sjögren-Larsson syndrome: Mutation analysis of Fatty Aldehyde Dehydrogenase Gene. Am J Hum Genet 65:1547–1560
Rizzo WB, Heinz E, Simo M, Craft DA (2000) Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implication for Sjögren-Larsson syndrome. Biochimica Biophysica Acta 1535:1–9
Sanlioglu S, Monick MM, Luleci G, Hunninghake GW, Engelhardt JF (2001) Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther 1:137–147
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112
Willemsen MA, Lutt MA, Steijlen PM, Cruysberg JR, van der Graaf M, Nijhuis-van der Sanden MW, Pasman JW, Mayatepek E, Rotteveel JJ (2001) Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr 160:711–717
Xiao X, Li J, Samulski RJ (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72:2224–2232
Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6:973–985
Acknowledgments
This work was supported by grants from the German Research Council/Deutsche Forschungsgemeinschaft (BR2004/1-1), Sander Stiftung (2003.117.1) and funds of the program for clinical research KKF, Klinikum Rechts der Isar, Technical University Munich. Work presented in this publication was performed as part of the doctoral thesis of S.H.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haug, S., Braun-Falco, M. Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjögren-Larsson syndrome. Arch Dermatol Res 296, 568–572 (2005). https://doi.org/10.1007/s00403-005-0556-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-005-0556-x